452 related articles for article (PubMed ID: 21740940)
21. Combinatorial targeting of cancer bone metastasis using mRNA engineered stem cells.
Segaliny AI; Cheng JL; Farhoodi HP; Toledano M; Yu CC; Tierra B; Hildebrand L; Liu L; Liao MJ; Cho J; Liu D; Sun L; Gulsen G; Su MY; Sah RL; Zhao W
EBioMedicine; 2019 Jul; 45():39-57. PubMed ID: 31281099
[TBL] [Abstract][Full Text] [Related]
22. Nano-engineered mesenchymal stem cells as targeted therapeutic carriers.
Sadhukha T; O'Brien TD; Prabha S
J Control Release; 2014 Dec; 196():243-51. PubMed ID: 25456830
[TBL] [Abstract][Full Text] [Related]
23. Inflammation and tumor microenvironments: defining the migratory itinerary of mesenchymal stem cells.
Spaeth E; Klopp A; Dembinski J; Andreeff M; Marini F
Gene Ther; 2008 May; 15(10):730-8. PubMed ID: 18401438
[TBL] [Abstract][Full Text] [Related]
24. Effective combination therapy for malignant glioma with TRAIL-secreting mesenchymal stem cells and lipoxygenase inhibitor MK886.
Kim SM; Woo JS; Jeong CH; Ryu CH; Lim JY; Jeun SS
Cancer Res; 2012 Sep; 72(18):4807-17. PubMed ID: 22962275
[TBL] [Abstract][Full Text] [Related]
25. Surface Functionalization of Polymeric Nanoparticles with Umbilical Cord-Derived Mesenchymal Stem Cell Membrane for Tumor-Targeted Therapy.
Yang N; Ding Y; Zhang Y; Wang B; Zhao X; Cheng K; Huang Y; Taleb M; Zhao J; Dong WF; Zhang L; Nie G
ACS Appl Mater Interfaces; 2018 Jul; 10(27):22963-22973. PubMed ID: 29905067
[TBL] [Abstract][Full Text] [Related]
26. MSC-Delivered Soluble TRAIL and Paclitaxel as Novel Combinatory Treatment for Pancreatic Adenocarcinoma.
Rossignoli F; Spano C; Grisendi G; Foppiani EM; Golinelli G; Mastrolia I; Bestagno M; Candini O; Petrachi T; Recchia A; Miselli F; Rovesti G; Orsi G; Veronesi E; Medici G; Petocchi B; Pinelli M; Horwitz EM; Conte P; Dominici M
Theranostics; 2019; 9(2):436-448. PubMed ID: 30809285
[TBL] [Abstract][Full Text] [Related]
27. The therapeutic potential of mesenchymal stem cells in lung cancer: benefits, risks and challenges.
Cortes-Dericks L; Galetta D
Cell Oncol (Dordr); 2019 Dec; 42(6):727-738. PubMed ID: 31254169
[TBL] [Abstract][Full Text] [Related]
28. Maximized nanodrug-loaded mesenchymal stem cells by a dual drug-loaded mode for the systemic treatment of metastatic lung cancer.
Yao S; Li X; Liu J; Sun Y; Wang Z; Jiang Y
Drug Deliv; 2017 Nov; 24(1):1372-1383. PubMed ID: 28920712
[TBL] [Abstract][Full Text] [Related]
29. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy.
Sasportas LS; Kasmieh R; Wakimoto H; Hingtgen S; van de Water JA; Mohapatra G; Figueiredo JL; Martuza RL; Weissleder R; Shah K
Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4822-7. PubMed ID: 19264968
[TBL] [Abstract][Full Text] [Related]
30. Cytokines play a key role in communication between mesenchymal stem cells and brain cancer cells.
Motaln H; Turnsek TL
Protein Pept Lett; 2015; 22(4):322-31. PubMed ID: 25642990
[TBL] [Abstract][Full Text] [Related]
31. Engineered adult stem cells: a promising tool for anti-cancer therapy.
Choi Y; Lee HK; Choi KC
BMB Rep; 2023 Feb; 56(2):71-77. PubMed ID: 36330711
[TBL] [Abstract][Full Text] [Related]
32. Perspectives in Engineered Mesenchymal Stem/Stromal Cells Based Anti- Cancer Drug Delivery Systems.
Ackova DG; Kanjevac T; Rimondini L; Bosnakovski D
Recent Pat Anticancer Drug Discov; 2016; 11(1):98-111. PubMed ID: 26554397
[TBL] [Abstract][Full Text] [Related]
33. Employing mesenchymal stem cells to support tumor-targeted delivery of extracellular vesicle (EV)-encapsulated microRNA-379.
O'Brien KP; Khan S; Gilligan KE; Zafar H; Lalor P; Glynn C; O'Flatharta C; Ingoldsby H; Dockery P; De Bhulbh A; Schweber JR; St John K; Leahy M; Murphy JM; Gallagher WM; O'Brien T; Kerin MJ; Dwyer RM
Oncogene; 2018 Apr; 37(16):2137-2149. PubMed ID: 29367765
[TBL] [Abstract][Full Text] [Related]
34. Potential implications of mesenchymal stem cells in cancer therapy.
Dai LJ; Moniri MR; Zeng ZR; Zhou JX; Rayat J; Warnock GL
Cancer Lett; 2011 Jun; 305(1):8-20. PubMed ID: 21396770
[TBL] [Abstract][Full Text] [Related]
35. Genetically engineered mesenchymal stem cells as a proposed therapeutic for Huntington's disease.
Olson SD; Pollock K; Kambal A; Cary W; Mitchell GM; Tempkin J; Stewart H; McGee J; Bauer G; Kim HS; Tempkin T; Wheelock V; Annett G; Dunbar G; Nolta JA
Mol Neurobiol; 2012 Feb; 45(1):87-98. PubMed ID: 22161544
[TBL] [Abstract][Full Text] [Related]
36. Mesenchymal Stem Cell-mediated delivery of the sodium iodide symporter supports radionuclide imaging and treatment of breast cancer.
Dwyer RM; Ryan J; Havelin RJ; Morris JC; Miller BW; Liu Z; Flavin R; O'Flatharta C; Foley MJ; Barrett HH; Murphy JM; Barry FP; O'Brien T; Kerin MJ
Stem Cells; 2011 Jul; 29(7):1149-57. PubMed ID: 21608083
[TBL] [Abstract][Full Text] [Related]
37. Engineering mesenchymal stem cells: a novel therapeutic approach in breast cancer.
Heidari R; Gholamian Dehkordi N; Mohseni R; Safaei M
J Drug Target; 2020; 28(7-8):732-741. PubMed ID: 32463709
[TBL] [Abstract][Full Text] [Related]
38. Mesenchymal stem cells for the sustained in vivo delivery of bioactive factors.
Meyerrose T; Olson S; Pontow S; Kalomoiris S; Jung Y; Annett G; Bauer G; Nolta JA
Adv Drug Deliv Rev; 2010 Sep; 62(12):1167-74. PubMed ID: 20920540
[TBL] [Abstract][Full Text] [Related]
39. Pathogenesis of metastatic disease: implications for current therapy and for the development of new therapeutic strategies.
Poste G
Cancer Treat Rep; 1986 Jan; 70(1):183-99. PubMed ID: 3510734
[TBL] [Abstract][Full Text] [Related]
40. Mesenchymal stem cells as therapeutics and vehicles for gene and drug delivery.
Porada CD; Almeida-Porada G
Adv Drug Deliv Rev; 2010 Sep; 62(12):1156-66. PubMed ID: 20828588
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
